BIO-Europe® 2016: InflaRX CEO highlights pipeline goals

December 6, 2016
Neils Riedemann, founder and CEO of InflaRX, speaks to Lucie Ellis, senior writer at Scrip, about the company's pipeline candidates, upcoming development targets, and long-term goals. InflaRX is developing highly specific monoclonal antibodies targeting activation products of the complement system and has made breakthrough discoveries in anti-C5a antibody generation, resulting in a new class of antibodies. The company's anti-complement technology is the basis for a pipeline of new antibodies addressing a broad variety of inflammatory diseases. Lead product, IFX-1, is currently in Phase II for early septic organ dysfunction.
Previous Video
BIO-Europe® 2016: Inositec CEO on 2017 financing plans
BIO-Europe® 2016: Inositec CEO on 2017 financing plans

Mattias Ivarsson, co-founder and CEO of Inositec, talks to Lucie Ellis, senior writer at Scrip, about the c...

Next Video
BIO-Europe® 2016: Atlantic Healthcare outlines filing plans
BIO-Europe® 2016: Atlantic Healthcare outlines filing plans

Toby Wilson Waterworth, CEO of Atlantic Healthcare, speaks to Mike Ward, global director of content for Inf...